Pharmacological targeting of TNS3 with histone deacetylase inhibitor as a therapeutic strategy in esophageal squamous cell carcinoma

Yang Shi; Zheng Xiang; Huiyu Yang; Suliman Khan; Ruizhe Li; Siran Zhou; Saif Ullah; Jiyu Zhang; Bingrong Liu

doi:doi:10.18632/aging.203091

← Back

Research Paper Volume 13, Issue 11 pp 15336—15352

Pharmacological targeting of TNS3 with histone deacetylase inhibitor as a therapeutic strategy in esophageal squamous cell carcinoma

Figure 3. TNS3 serves as an oncogene in ESCC based on public databases. (A) TNS3 expression in ESCC compared with the corresponding paracancerous tissues in GEO database, including GSE20347, GSE23400, and GSE44021 [17–19]. (B) TNS3 expression in ESCC, the related paracancerous tissues, and related normal tissues (GSE161533). (C) TNS3 expression in EC cells (ESCC OE21 and EAC OE33) treated with MS275 and AZA (GSE57130 [23]). (D) TNS3 expression among different clinical TNM stage (left) and histopathological grade (right) of ESCC in TCGA database. (E) Correlations between TNS3 and c-Src in normal tissues based on GTEx database.